Performance of the sōna Aspergillus Galactomannan Lateral Flow Assay in a Cancer Patient Population-Reference-Cited by-同舟云学术

Performance of the sōna Aspergillus Galactomannan Lateral Flow Assay in a Cancer Patient Population

Published:2021-08-18 Issue:9 Volume:59 Page:
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Jani Krupa¹,McMillen Tracy¹,Morjaria Sejal²,Babady N. Esther¹²^ORCID

Affiliation:

1. Clinical Microbiology Service, Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA

2. Infectious Diseases Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA

Abstract

The diagnosis of invasive aspergillosis can be challenging in cancer patients. Herein, the analytical and clinical performance of the sōna Aspergillus galactomannan lateral flow assay (GM LFA) was evaluated and its performance compared to that of the Bio-Rad galactomannan enzyme immunoassay (GM EIA).

Funder

HHS | NIH | National Cancer Institute

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.00598-21

Reference16 articles.

1. Pathogenesis of Aspergillus fumigatus in Invasive Aspergillosis

2. Chemotherapy-induced neutropenia

3. Current Challenges in the Diagnosis of Fungal Infections